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Purpose: Platelet-derived growth factor (PDGF) and insulin promote the survival of neuronal cells, including retinal
ganglion cells (RGCs), via activation of phosphoinositide 3-kinase (PI 3-kinase)/Akt signaling. Of importance, recent
studies have shown that imatinib inhibition of PDGF receptors induces retinal toxicity in some patients. To date, the extent
of activation and the functional significance of insulin-induced PI 3-kinase/Akt signaling remain unclear in the context
of dysregulated PDGF receptor signaling in retinal cells. In the present study, we tested the hypothesis that the pro-survival
effect of insulin-induced PI 3-kinase/Akt signaling is compromised by imatinib inhibition of PDGF receptor signaling in
RGCs.
Methods: RGC-5 cells were subjected to acute and long-term treatments with imatinib, a PDGF receptor tyrosine kinase
inhibitor. Afterwards, the changes in RGC phenotype and apoptotic markers were assessed by fluorescence and phase
contrast microscopy and caspase-3/poly(ADP-ribose) polymerase (PARP) cleavage, respectively. In addition, imatinib
regulation of PDGF- and insulin-induced PI 3-kinase/Akt survival signaling was determined by immunoblot analyses,
immunoprecipitation, and in vitro PI 3-kinase assays.
Results: Treatment of RGC-5 cells with imatinib for up to 48 h resulted in apoptosis, which was not rescued by insulin
supplementation. The apoptotic phenotype was associated with upregulation of cleaved caspase-3 and cleaved poly(ADP-
ribose) polymerase. Time dependency experiments revealed that imatinib-mediated apoptosis was preceded by early and
sustained abrogation of PDGF-induced increases in PDGF receptor tyrosine phosphorylation and phosphotyrosine-
associated PI 3-kinase activity. In addition, imatinib inhibited PDGF-induced downstream phosphorylation of Akt,
GSK-3β, and p70S6kinase. However, imatinib exposure did not affect insulin-induced insulin receptor substrate (IRS)-
associated PI 3-kinase activity and the downstream phosphorylation of Akt, GSK-3β, and p70S6kinase.
Conclusions: Together, these data indicate that disruption of PDGF receptor signaling compromises the pro-survival
effect of insulin-induced IRS-dependent PI 3-kinase/Akt signaling in RGCs, and that the maintenance of PDGF-induced
PI 3-kinase/Akt signaling is critical for the survival of retinal neuronal cells.
The central nervous system consists of different neuronal
cell types, including retinal, cerebellar, and cortical neuronal
cells [1], the survival of which depends in part on insulin
receptor signaling [2-9]. Impaired insulin receptor stimulation
of survival signals such as insulin receptor substrate (IRS)-
associated phosphoinositide 3-kinase (PI 3-kinase) and Akt
results in caspase-3 activation and apoptotic cell death in
neurons  [4,6,10].  Genetic  ablation  of  rod  photoreceptor-
specific insulin receptors in mouse retinas results in light-
induced photoreceptor degeneration, which is characterized
by diminished PI 3-kinase/Akt activation [6]. In addition,
deficiency of insulin receptor substrate-2 (IRS-2) in mice
induces ganglion cell and photoreceptor loss, associated with
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diminished Akt activation and increased caspase-3 activation
[11]. In brain/neuron-specific insulin receptor knockout mice,
insulin cannot induce IRS-associated PI 3-kinase activity and
Akt phosphorylation to prevent neuronal cell apoptosis [9].
These studies clearly demonstrate that the maintenance of
functional insulin receptor survival signaling is pivotal to the
viability of postmitotic neurons.
Platelet-derived  growth  factor  (PDGF)  is  another
important neurotrophin that promotes the survival of central
nervous  system  neurons,  including  retinal  ganglion  cells
(RGCs).  In  this  regard,  PDGF  induces  PI  3-kinase/Akt
survival signaling to prevent apoptotic cell death [12-15].
Transection  of  the  optic  nerve  is  associated  with  RGC
apoptosis,  and  this  has  been  attributed  to  diminished
expression levels of PDGF [16,17]. Mouse brains deficient in
neuronal PDGF receptor-β are vulnerable to cerebral damage
as revealed by increased neuronal cell death in response to N-
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1599methyl-D-aspartate  [18].  These  studies  suggest  that  the
maintenance of functional PDGF receptor signaling is also
important in promoting neuronal cell survival.
Recent studies have shown that imatinib inhibition of
PDGF  receptors  induces  retinal  toxicity  in  patients  with
chronic  myeloid  leukemia  (CML)  [19-23].  These
observations  suggest  that  imatinib  treatment  would  affect
PDGF-induced  PI  3-kinase/Akt  survival  signaling,  which
however has not been examined in retinal cells, including
RGCs. Furthermore, imatinib therapy in CML patients with
diabetes  improves  insulin  sensitivity  and  fasting  blood
glucose levels [24,25]. These findings raise the possibility that
imatinib inhibition of PDGF receptors may enhance insulin-
induced pro-survival signaling. On the contrary, recent studies
with  hepatoma  cells  have  shown  that  imatinib  attenuates
insulin-induced  phosphorylation  of  Akt  and  glycogen
synthase kinase-3β (GSK-3β) [26]. Hence, it is important to
compare  the  effects  of  imatinib  on  PDGF-versus  insulin-
induced PI 3-kinase/Akt signaling and retinal cell survival. In
the  present  study,  we  tested  the  hypothesis  that  the  pro-
survival effect of insulin-induced PI 3-kinase/Akt signaling is
compromised  by  imatinib  inhibition  of  PDGF  receptor
signaling in RGCs.
It is widely known that insulin and PDGF activate PI 3-
kinase via IRS-dependent and IRS-independent mechanisms,
respectively [12,27,28]. Insulin receptor stimulation promotes
tyrosine phosphorylation of insulin receptor substrates (IRS-1
and IRS-2) to recruit p85 regulatory subunits of PI 3-kinase,
whereas  PDGF  promotes  PDGF  receptor  tyrosine
phosphorylation  to  recruit  p85  regulatory  subunits.  The
recruitment  of  p85  regulatory  subunit  leads  to  a
conformational  change  in  the  p110  catalytic  subunit  to
activate PI 3-kinase. The isoforms of p85 regulatory subunit
include p85α, p85β, and the splice variants (p55γ, p55α, and
p50α) and those of p110 catalytic subunit include p110α,
p110β, and p110δ, and they belong to class IA PI 3-kinase
[29]. Importantly, class IA PI 3-kinase activation constitutes a
major  source  for  the  generation  of  different
phosphatidylinositol 3,4,5-trisphosphate (PIP3) lipid species
[29,30]. Insulin or PDGF stimulation of class IA PI 3-kinase
enhances  cellular  levels  of  PIP3,  which  results  in  the
phosphorylation  of  downstream  effectors,  including  Akt,
glycogen synthase kinase-3β (GSK-3β), and p70S6kinase. To
date, insulin and PDGF stimulation of retinal cell class IA PI
3-kinase  and  its  downstream  effectors  have  not  been
examined  in  parallel,  particularly  in  the  context  of
dysregulated PDGF receptor signaling.
To determine the functional consequences of impaired
PDGF  receptor  signaling  on  neuronal  cell  phenotype,  we
exposed RGC-5 retinal neuronal cells in culture to imatinib,
a PDGF receptor tyrosine kinase inhibitor. After acute and
long-term treatments with imatinib, we examined the changes
in RGC phenotype and the associated changes in apoptotic
markers. In addition, we performed a detailed analysis of PI
3-kinase/Akt survival signaling by determining PDGF- and
insulin-induced  changes  in  PI  3-kinase  activity  and  the
phosphorylation  of  downstream  effectors  such  as  Akt,
GSK-3β, and p70S6kinase.
METHODS
Materials:  Recombinant  human  platelet-derived  growth
factor-BB (PDGF-BB) was purchased from R&D Systems
(Minneapolis, MN). Human insulin (Novolin R) and imatinib
mesylate (Gleevec®) were obtained from Hershey Medical
Center Pharmacy (Hershey, PA). The primary antibodies for
PDGFR-β (28E1), phospho-PDGFR β (Tyr751), phospho-
IGF-1 receptor/insulin receptor, phospho-Akt (Ser473), Akt,
phospho-GSK-3β,  phospho-p70S6kinase  (Thr421/Ser424),
caspase-3, and poly(ADP-ribose) polymerase (PARP) were
purchased from Cell Signaling (Beverly, MA). The primary
antibodies for phosphotyrosine (clone 4G10), p85α (N-SH2,
clone  UB93–3),  and  p110β  were  purchased  from  Upstate
Biotechnology/Chemicon/Millipore  (Temecula,  CA).  The
primary  antibodies  for  IRS-1  and  insulin  receptor-β  were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
The primary antibody for β-actin was purchased from Novus
Biologicals (Littleton, CO). Silica gel 60 TLC plates were
purchased  from  EMD  Biosciences  (San  Diego,  CA).
[γ-32P]ATP (sp. activity: 4,500 Ci/mmol) was purchased from
MP Biomedicals (Solon, OH). All other chemicals were from
Fisher Scientific (Fair Lawn, NJ) or Sigma Chemical (St.
Louis, MO).
Cell culture and treatments: The rat retinal ganglion cell line
(RGC-5) was obtained as a gift from Dr. Neeraj Agarwal
(University  of  North  Texas  Health  Science  Center,  Fort
Worth,  Texas).  RGC-5  cells  (passages  up  to  10)  were
maintained  in  culture  using  Dulbecco’s  Modified  Eagle
Medium (Invitrogen, Carlsbad, CA) along with 10% fetal
bovine  serum  (HyClone,  Logan,  UT)  and  antibiotic  and
antimycotic solution (Sigma) in a humidified atmosphere of
95%  air  and  5%  CO2,  as  described  [12,31].  After  the
attainment of confluence, RGC-5 cells were trypsinized and
seeded on to either 100 mm or 60 mm Petri dishes or 6 well
plates. The subconfluent cells were then subjected to serum
deprivation for 24 h, treated with 0.1 µM to 30 µM imatinib,
and stimulated with either 30 ng/ml PDGF or 30 nM insulin
for 6 min. Control and treated cells were washed with ice-cold
phosphate buffered saline (PBS, HyClone), and lysed with
laemmli sample buffer (for immunoblotting) or snap frozen
using  buffer  A  (for  immunoprecipitation/in  vitro  kinase
assays). Buffer A consisted of 50 mM Tris-HCl (pH 7.5), 0.1%
Triton X-100, 1 mM EDTA, 1 mM EGTA, 50 mM sodium
fluoride, 10 mM sodium β-glycerophosphate, 5 mM sodium
pyrophosphate,  1  mM  sodium  orthovanadate,  protease
inhibitor  cocktail  (Sigma),  0.1%  β-mercaptoethanol,  and
1 µM LR-microcystin.
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1600Fluorescence and phase contrast microscopy: RGC-5 cells
were seeded onto 6 well plates. The subconfluent cells were
then maintained in complete medium (+FBS) or serum free
medium (-FBS) for 48 h, during which time the cells were
exposed to increasing concentrations of imatinib (1 µM to
30  µM).  In  addition,  serum-free  medium  (-FBS)  was
supplemented with either 30 ng/ml PDGF or 30 nM insulin
during RGC-5 cell exposure to imatinib. After 48 h, the cells
were  washed  with  PBS  (pH  7.4),  fixed  with  4%
paraformaldehyde for 15 min, and then labeled with 0.5 µg/
ml  4,6  diamidino-2-phenylindole  (DAPI).  The  apoptotic
phenotype was then assessed by nuclear staining with DAPI
(fluorescence  microscopy)  and  by  morphological  changes
(phase-contrast microscopy). For each treatment condition, at
least 3 different fields were chosen to verify apoptotic cell
death  characterized  by  nuclear  condensation,  cytoplasmic
shrinkage, and rounding-up of cells. The images of RGC-5
cells  obtained  from  fluorescence  and  phase-contrast
microscopy are representative of 4 to 5 separate experiments.
Immunoblot analysis: RGC-5 cell lysates (10 µg protein each)
were electrophoresed using pre-cast 4%–12% NuPage mini-
gels (Invitrogen), and the resolved proteins were transferred
to  nitrocellulose  membranes  (Hybond  C;  Amersham
Biosciences). The membranes were blocked and probed with
the  respective  primary  antibodies.  The  membranes  were
washed three times with Tris-buffered saline (TBS, pH 7.5).
The components of TBS included 25 mM Tris base, 137 mM
NaCl, 3 mM KCl, and 0.1% Tween-20. Subsequently, the
immunoreactivity  was  detected  using  specific  HRP-
conjugated  secondary  antibodies  followed  by  enhanced
chemiluminescence (Amersham Biosciences), as described
[12]. The protein bands were quantified using Biorad GS-800
calibrated densitometer.
Immunoprecipitation  of  tyrosine  phosphorylated  proteins,
IRS-1, p85α, or p110β subunits: RGC-5 lysates obtained using
buffer A were sonicated (15 s×4) and centrifuged at 16,000x
g (4 °C) for 10 min. The respective supernatants were then
used for protein assays (Coomassie protein reagent, Pierce,
Rockford, IL). The aliquots of supernatants (60 µg protein)
were subjected to immunoprecipitation (4 °C, overnight) with
2 µg each of anti-phosphotyrosine, anti-IRS-1, anti-p85α, or
anti-p110β primary antibody that was pre-conjugated (2 h at
4 °C) to Gammabind G Sepharose. Prior to the PI 3-kinase
assays, the immunocomplexes were washed with buffer A and
TNE buffer, which consisted of 10 mM Tris-HCl (pH 7.4),
150  mM  NaCl,  5  mM  EGTA,  and  0.1  mM  sodium
orthovanadate [12].
In vitro PI 3-kinase assays: PI 3-kinase assays were performed
according  to  the  following  protocol  [12].  After
immunoprecipitation  of  proteins  using  specific  primary
antibodies, the respective immunocomplexes were subjected
to PI 3-kinase assays by incubation at 35 °C for 10 min in the
presence  of  50  µl  TNE  buffer  (pH  7.4),  20  µg/assay
phosphatidylinositol substrate, and 10 µCi/assay γ-32P-ATP.
The reactions were stopped by adding 20 µl of 6N HCl and
160 µl of CHCl3/CH3OH (1:1). Subsequently, the assay tubes
were vortexed for 20 s and centrifuged at 16,000 xg at room
temperature for 5 min. The phospholipid-containing lower
organic  phase  from  the  respective  reaction  tubes  was
recovered  and  spotted  on  to  silica  gel  thin  layer
chromatography plates that had been heated to 100 °C for
approximately 1 h. The thin layer chromatography plates were
then subjected to ascending chromatography using a freshly
prepared solvent mixture that contained (in ml) 60 CHCl3; 47
CH3OH;  11.3  H2O;  2  NH4OH.  Phosphatidylinositol  3-
phosphate (PI3P) spots thus resolved were visualized and
quantified by autoradiography and phosphorimager analyses
(Molecular  Dynamics,  Sunnyvale,  CA),  respectively.  As
negative  controls,  mock  immunoprecipitations  were
performed  using  lysis  buffer,  which  revealed  negligible
formation of 32P-labeled PI3P.
Statistical analyses: Results shown are the mean±standard
error  of  the  mean  of  3  or  more  experiments.  Statistical
analyses of the data were performed by one-way repeated
measures ANOVA followed by Bonferroni t-test. Values of
p<0.05 were considered statistically significant.
RESULTS
Imatinib  induces  RGC  apoptosis  with  or  without  PDGF/
insulin  exposure:  Previously,  we  and  several  other
investigators  showed  that  PDGF  or  insulin  promotes  the
survival of neuronal cells, including RGCs [3,4,12]. In the
present study, we examined the effects of imatinib, a PDGF
receptor tyrosine kinase inhibitor, on the phenotypic changes
in RGC-5 cells. Initial experiments involved the maintenance
of subconfluent RGC-5 cells in complete medium (+FBS) for
48 h, during which time the cells were exposed to increasing
concentrations  of  imatinib  (1  µM  to  30  µM)  and  then
examined for phenotypic changes. Figure 1A shows that in
comparison  with  control,  imatinib  treatments  with  10  to
30 µM concentrations for 48 h caused progressive increases
in nuclear condensation as revealed by nuclear staining with
DAPI (fluorescence microscopy) and cytoplasmic shrinkage
and  rounding  up  of  cells  as  revealed  by  phase-contrast
microscopy.  In  addition,  imatinib  produced  similar
phenotypic changes in RGC-5 cells maintained under serum-
free conditions in the absence (Figure 1B) or presence of
PDGF (Figure 1C), or insulin (Figure 1D). These data suggest
that PDGF receptor tyrosine kinase inhibition by imatinib has
the  potential  to  induce  RGC  apoptosis,  and  that
supplementation with neurotrophic factors such as PDGF or
insulin under these conditions may not rescue apoptotic cell
death.
Imatinib induces caspase-3/PARP cleavage and diminishes
Akt phosphorylation in RGCs: Apoptotic cell death is induced
by the upregulation of cleaved caspase-3 and cleaved PARP.
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caspase-3, whereas nuclear PARP is one of the substrates of
activated caspase-3. The activation of caspase-3 may result
from diminution in the phosphorylation or activation of cell
survival  kinases,  including  Akt,  and  so  we  examined  if
imatinib  perturbs  these  pathways  in  RGC-5  cells.
Subconfluent  RGC-5  cells  were  maintained  in  serum-free
conditions for 24 h or 48 h, during which time the cells were
exposed to 10 µM and 30 µM imatinib. The cell lysates were
subjected  to  immunoblotting  using  the  following  primary
antibodies:  anti-caspase-3  primary  antibody  that  detects
endogenous full length inactive caspase-3 (35 kDa) and the
cleaved  caspase-3  (19  kDa;  Figure  2A);  and  anti-PARP
primary antibody that detects endogenous full length PARP
Figure  1.  Concentration  dependency  for  imatinib-induced
phenotypic changes in RGC-5 cells. Subconfluent RGC-5 cells were
maintained in complete medium (+FBS) or serum-free medium (-
FBS) for 48 h, during which time the cells were exposed to increasing
concentrations of imatinib (1 µM to 30 µM; A, B). In addition, serum-
free medium (-FBS) was supplemented with either 30 ng/ml PDGF
or 30 nM insulin during RGC-5 cell exposure to imatinib (C, D). The
apoptotic phenotype was then assessed by nuclear DAPI staining
(fluorescence  microscopy)  and  morphological  changes  (phase-
contrast microscopy). The images shown are representative of 4 to 5
separate experiments.
(116  kDa)  and  the  catalytic  domain-containing  cleaved
fragment  (89  kDa;  Figure  2B).  Figure  2A  shows  that  in
comparison with control, imatinib treatments at 10 µM and
30 µM concentrations for 24 h did not produce significant
increases in cleaved caspase-3 expression. However, when the
incubation time was prolonged to 48 h, there were progressive
increases in the upregulation of cleaved caspase-3. As shown
in Figure 2A, 10 µM and 30 µM imatinib caused significant
increases in the expression levels of cleaved caspase-3 by
approximately 4.4 fold and 17.3 fold, respectively, compared
with the respective control at the 48 h time point. In a similar
manner,  imatinib  treatments  at  10  µM  and  30  µM
concentrations for 48 h caused progressive increases in the
expression levels of cleaved PARP (Figure 2B). The graph
shows  that  30  µM  imatinib  increased  the  expression  of
cleaved  PARP  by  roughly  8.7  fold,  compared  with  the
respective control at the 48 h time point. The upregulation of
cleaved  caspase-3  and  cleaved  PARP  was  preceded  by
sustained diminutions in Akt Ser473 phosphorylation, as can
be seen with 10 µM and 30 µM imatinib treatments for 24 h
or 48 h (Figure 2C). These data suggest that inhibition of
PDGF receptor tyrosine kinase by imatinib may suppress the
activation of lipid kinase (PI 3-kinase) upstream of Akt and
the phosphorylation of protein kinases downstream of PI 3-
kinase. It is therefore important to examine whether imatinib
induces  RGC  apoptosis  by  dysregulating  agonist-specific
activation  of  lipid  kinase  and  protein  kinase  survival
signaling.
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Acute  imatinib  treatment  inhibits  PDGF  but  not  insulin
receptor  phosphorylation:  To  determine  whether  imatinib
dysregulates  agonist-specific  receptor  tyrosine
phosphorylation, we subjected serum-deprived (24 h) RGC-5
cells to pretreatments without (control) or with imatinib (0.1
to 30 µM) for 30 min. Subsequently, control and imatinib-
pretreated cells were stimulated with PDGF or insulin for 6
min. As shown in Figure 3A, PDGF stimulation of RGC-5
cells  resulted  in  robust  increases  in  PDGFR  tyrosine
phosphorylation compared with control, and pretreatment of
RGC-5  cells  with  increasing  concentrations  of  imatinib
attenuated PDGF-induced PDGFR tyrosine phosphorylation.
The extent of decreases in PDGF-induced PDGFR tyrosine
phosphorylation  with  imatinib  at  0.1,  1,  10,  and  30  µM
concentrations were 47%, 96%, 99%, and 99%, respectively
(p<0.05). Figure 3B shows that insulin receptors are tyrosine
phosphorylated  in  RGC-5  cells  under  basal  conditions,
characteristic of constitutively active insulin receptors in the
rodent  retinas  [10,32].  Notably,  imatinib  did  not  inhibit
insulin-induced insulin receptor tyrosine phosphorylation at
any of the concentrations used in this study (Figure 3B). These
data  support  the  specificity  of  imatinib  toward  inhibiting
PDGFR tyrosine kinase and the lack of its inhibitory effects
on insulin receptor tyrosine kinase activity.Acute  imatinib  treatment  inhibits  PDGF-induced  but  not
insulin-induced PI 3-kinase: Previous studies have shown that
Figure 2. Concentration-dependent effects of imatinib on caspase-3/
PARP cleavage and Akt phosphorylation. Subconfluent RGC-5 cells
were maintained in serum free medium (-FBS) for 24 h or 48 h,
during  which  time  the  cells  were  exposed  to  increasing
concentrations of imatinib (10 µM to 30 µM). The cell lysates were
subjected to immunoblot analysis using primary antibodies specific
for A) caspase-3 that detects full-length and cleaved caspase-3, and
B) PARP that detects full-length PARP and cleaved PARP, and C)
phospho-Akt(Ser473) and total Akt. To normalize the expression of
cleaved caspase-3 and cleaved PARP and the phosphorylation of
Akt, we used the housekeeping gene β-actin as an internal control.
The respective bar graphs shown are the mean±SEM values from 3
to 5 experiments. The asterisk and the sharp (hash mark) indicate a
p<0.05 compared with the respective controls.
imatinib  inhibits  PDGF-induced  Akt  phosphorylation  in
vascular smooth muscle cells [33] and IRS-associated PI 3-
kinase  activity  in  leukemia  cells  [34,35].  These  findings
suggest the potential for imatinib to inhibit PDGF receptor-
associated PI 3-kinase as well as IRS-associated PI 3-kinase
activity in a cell type-specific manner. In the present study,
we therefore examined the effects of imatinib on PDGF- and
insulin-induced PI 3-kinase activity in RGC-5 cells. As shown
in Figure 4A,B, PDGF stimulation of RGC-5 cells for 6 min
resulted  in  robust  increases  in  phosphotyrosine-associated
(Figure 4A) and p85α-associated PI 3-kinase activity (Figure
4B), which was inhibited by pretreatments with increasing
concentrations of imatinib for 30 min. The diminished PI 3-
kinase  activity  was  due  to  imatinib  inhibition  of  p85α
recruitment  by  PDGF  (Figure  4A)  without  affecting  the
expression  of  p85α  (Figure  4B).  At  10  µM  imatinib
concentration,  PDGF-induced  phosphotyrosine-  and  p85α-
associated PI 3-kinase activity declined to values comparable
to the basal PI 3-kinase activity. In contrast, imatinib did not
inhibit insulin-induced IRS-1 association with p85α or IRS-1-
associated PI 3-kinase activity at any of the concentrations
used in this study (Figure 4C). These data further support the
specificity of imatinib action in that it inhibits PDGF receptor
tyrosine  phosphorylation  to  inhibit  p85α  recruitment  and
consequently    attenuates    phosphotyrosine-    and     p85α-
associated PI 3-kinase activity. In parallel, imatinib did not
Figure 3. Concentration-dependent effects of imatinib on PDGF-
induced versus insulin-induced receptor phosphorylation. Serum-
deprived (24 h) RGC-5 cells were pretreated without (control) or with
increasing concentrations of imatinib (0.1 µM to 30 µM) for 30 min.
Subsequently,  control  and  imatinib-treated  cells  were  stimulated
with either 30 ng/ml PDGF or 30 nM insulin for 6 min. The cell
lysates were subjected to immunoblot analysis for receptor tyrosine
phosphorylation (A, B) using the indicated primary antibodies (See
Methods). To normalize the changes in protein phosphorylation in
the immunoblots, β-actin was used as an internal control. Note: For
data analyses, PDGF- or insulin-induced receptor phosphorylation
in the absence of imatinib was normalized to 100%. The respective
linear graphs shown are the mean±SEM values from 3 experiments.
The asterisk denotes a p<0.05 compared with the respective PDGF-
induced receptor phosphorylation.
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phosphorylation,  p85α  recruitment  to  IRS-1,  and  IRS-1
associated PI 3-kinase activity in RGC-5 cells.
Acute  imatinib  treatment  inhibits  PDGF-induced  but  not
insulin-induced  Akt/GSK-3β/p70S6kinase  phosphorylation:
The data shown in Figure 3 and Figure 4 suggest that imatinib
may cause selective inhibition of PDGF-induced PI 3-kinase
downstream signaling events, including Akt, GSK-3β, and
p70S6kinase  phosphorylation  without  affecting  insulin-
induced Akt signaling. Recent studies with hepatoma cells
have shown that imatinib inhibits c-Abl cytosolic tyrosine
kinase to attenuate insulin-induced but not IGF-1-induced
Figure 4. Concentration-dependent effects of imatinib on PDGF-
induced versus insulin-induced PI 3-kinase. Serum-deprived (24 h)
RGC-5 cells were pretreated without (control) or with increasing
concentrations  of  imatinib  (0.1  µM  to  30  µM)  for  30  min.
Subsequently,  control  and  imatinib-treated  cells  were  stimulated
with either 30 ng/ml PDGF or 30 nM insulin for 6 min. The cell
lysates were subjected to immunoprecipitation followed by PI 3-
kinase assays or immunoblot analysis (A-C) using the indicated
primary  antibodies  (see  Methods).  The  representative  thin  layer
chromatogram  and  the  immunoblots  for  imatinib  regulation  of
PDGF-induced PI 3-kinase activity (A, B) and insulin-induced PI 3-
kinase activity (C) are shown. Note: For data analyses, PDGF- or
insulin-induced PI 3-kinase activity in the absence of imatinib was
normalized to 100%. The respective linear graphs shown are the
mean±SEM values from 3 experiments. The asterisk indicates a
p<0.05 compared with the respective PDGF-induced PI 3-kinase
activity.
phosphorylation  of  Akt  and  GSK-3β  [26].  Hence,  it  is
important  to  examine  the  selectivity  of  imatinib  toward
inhibiting agonist-specific signaling events even at the level
of protein phosphorylation downstream of PI 3-kinase. In the
present study, acute imatinib pretreatment caused progressive
decreases in PDGF-induced (Figure 5A-C) but not insulin-
induced (Figure 5D-F) phosphorylation of Akt, GSK-3β, and
p70S6kinase. These data suggest that c-Abl may not be a
likely  intermediary  component  for  insulin-induced  Akt
signaling events in RGC-5 cells.
Figure 5. Concentration-dependent effects of imatinib on PDGF-
induced  versus  insulin-induced  Akt/GSK-3β/p70S6kinase
phosphorylation.  Serum-deprived  (24  h)  RGC-5  cells  were
pretreated without (control) or with increasing concentrations of
imatinib (0.1 µM to 30 µM) for 30 min. Subsequently, control and
imatinib-treated cells were stimulated with either 30 ng/ml PDGF or
30  nM  insulin  for  6  min.  The  cell  lysates  were  subjected  to
immunoblot  analysis  for  Akt,  GSK-3β,  and  p70S6  kinase
phosphorylation  (A-C,  and  D-F)  using  the  indicated  primary
antibodies  (see  Methods).  To  normalize  the  changes  in  protein
phosphorylation in the immunoblots, we used β-actin as an internal
control. Note: For data analyses, PDGF- or insulin-induced protein
kinase phosphorylation in the absence of imatinib was normalized to
100%. The respective linear graphs shown are the mean±SEM values
from 3 experiments. The asterisk indicates a p<0.05 compared with
the respective PDGF-induced protein kinase phosphorylation..
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insulin-induced PI 3-kinase: Recent studies demonstrate that
prolonged incubation of leukemia cells with imatinib results
in the generation of endogenous ceramides [36], which may
mediate apoptotic cell death by inhibiting PDGF- and insulin-
induced PI 3-kinase activity [37]. In this regard, treatment of
rat retinal neuronal cells with C2-ceramide inhibits insulin-
induced  IRS-associated  PI  3-kinase  activity  (unpublished
observations). To verify whether long-term imatinib exposure
affects PDGF as well as insulin-induced PI 3-kinase activity,
Figure  6.  Time-dependent  effects  of  imatinib  on  PDGF-induced
versus insulin-induced receptor phosphorylation. Serum-deprived
(24 h) RGC-5 cells were pretreated without (control) or with 10 µM
imatinib for increasing time intervals (3 h and 24 h). Subsequently,
control and imatinib-treated cells were stimulated with either 30 ng/
ml PDGF or 30 nM insulin for 6 min. The cell lysates were subjected
to immunoblot analysis for receptor tyrosine phosphorylation (A,B)
using the indicated primary antibodies (See Methods). To normalize
the changes in protein phosphorylation in the immunoblots, we used
β-actin as an internal control. Note: For data analyses, PDGF- or
insulin-induced receptor phosphorylation in the absence of imatinib
was normalized to 100%. The respective bar graphs shown are the
mean±SEM values from 3 to 4 experiments. The asterisk indicates a
p<0.05  compared  with  the  respective  PDGF-induced  receptor
phosphorylation.
further  studies  were  performed.  As  shown  in  Figure  7A,
imatinib pretreatments for 3 h and 24 h completely abolished
PDGF-induced  phosphotyrosine-associated  PI  3-kinase
activity. In contrast, imatinib pretreatments for 3 h and 24 h
did not cause significant changes in insulin-induced PI 3-
kinase  activity  associated  with  phosphotyrosine,  IRS-1,
p85α, and p110β immunocomplexes (Figure 7B-E). Thus,
assessment of insulin-induced PI 3-kinase activity at the level
of tyrosine phosphorylated proteins, IRS-1 adaptor molecule,
p85  regulatory,  and  p110  catalytic  subunits  reveals  that
insulin-induced PI 3-kinase activation is refractory to imatinib
treatment. Overall, the present findings support the specificity
of long-term imatinib treatment in inhibiting PDGF receptor-
mediated PI 3-kinase activation while maintaining insulin
receptor-mediated IRS signaling in RGC-5 cells.
Prolonged imatinib treatment inhibits PDGF-induced but not
insulin-induced  Akt/GSK-3β/p70S6kinase  phosphorylation:
To further support the observations shown in Figure 6 and
Figure  7,  we  examined  the  effects  of  long-term  imatinib
exposure under similar conditions. As shown in Figure 8A-C,
imatinib pretreatments for 3 h and 24 h completely abolished
PDGF-induced  phosphorylation  of  Akt,  GSK-3β,  and
p70S6kinase, but not insulin-induced phosphorylation of Akt,
GSK-3β,  and  p70S6kinase  (Figure  8D-F).  Together,  the
present study demonstrates that acute or chronic exposure to
imatinib inhibits PDGF-induced PI 3-kinase/Akt signaling but
maintains  an  apparent  insulin-induced  PI  3-kinase/Akt
prosurvival signaling.
DISCUSSION
The  present  study  provides  evidence  that  the  survival  of
RGCs, a key component of the central nervous system, is
compromised by impaired PDGF receptor signaling. Imatinib
inhibition of PDGF receptor signaling leads to apoptotic cell
death, which is not rescued by insulin that triggers prosurvival
signaling  pathway  (Figure  9).  The  major  findings  of  the
present study are as follows: 1) RGCs that possess functional
PDGF  receptors  and  insulin  receptors  undergo  apoptosis
characterized by upregulation of cleaved caspase-3 and PARP
after exposure to imatinib, an inhibitor of PDGF receptor
tyrosine kinase; 2) the apoptotic phenotype resulting from
inhibition of PDGF receptor tyrosine kinase is not rescued by
insulin,  a  neuroprotective  agonist;  3)  specifically,  the
apoptotic effect of imatinib is preceded by early and sustained
inhibition of PDGF-induced signaling events such as PDGF
receptor  tyrosine  phosphorylation,  phosphotyrosine-  and
p85α-associated  PI  3-kinase  activity,  and  downstream
phosphorylation of Akt, GSK-3β, and p70S6kinase; and 4)
imatinib does not affect insulin-induced signaling events such
as  IRS-  and  p85α-associated  PI  3-kinase  activity  and
downstream  phosphorylation  of  Akt,  GSK-3β,  and
p70S6kinase,  which,  however,  do  not  prevent  imatinib-
induced  apoptosis.  Together,  these  data  suggest  that  an
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Prolonged imatinib treatment inhibits PDGF but not insulin
receptor phosphorylation: To determine the sustained effects
of  imatinib  that  dysregulates  agonist-specific  receptor
tyrosine phosphorylation, we subjected serum-deprived (24
h) RGC-5 cells to pretreatments without (control) or with
10 µM imatinib for 3 h and 24 h. Subsequently, control and
imatinib-pretreated  cells  were  stimulated  with  PDGF  or
insulin  for  6  min.  As  shown  in  Figure  6A,  imatinib
pretreatments for 3 h and 24 h completely abolished PDGF-
induced PDGF receptor tyrosine phosphorylation. In contrast,
even after prolonged incubation with imatinib for 3 h and 24
h, there were no decreases in insulin-induced insulin receptor
tyrosine phosphorylation (Figure 6B). Thus, the data shown
in Figure 3A,B and Figure 6A,B indicate that acute or chronic
exposure  to  imatinib  maintains  its  specificity  toward
inhibiting PDGF receptor tyrosine kinase.imbalance in PI 3-kinase activation resulting from impaired
PDGF receptor-mediated p85α recruitment and normal IRS-
mediated p85α recruitment may compromise the coordinated
Figure  7.  Time-dependent  effects  of  imatinib  on  PDGF-induced
versus insulin-induced PI 3-kinase. Serum-deprived (24 h) RGC-5
cells were pretreated without (control) or with 10 µM imatinib for
increasing time intervals (3 h and 24 h). Subsequently, control and
imatinib-treated cells were stimulated with either 30 ng/ml PDGF or
30  nM  insulin  for  6  min.  The  cell  lysates  were  subjected  to
immunoprecipitation followed by PI 3-kinase assays or immunoblot
analysis (A and B-E) using the indicated primary antibodies (see
Methods).  The  representative  thin  layer  chromatogram  and  the
immunoblots for imatinib regulation of PDGF-induced PI 3-kinase
activity  (A)  and  insulin-induced  PI  3-kinase  activity  (B-E)  are
shown. Note: For data analyses, PDGF- or insulin-induced PI 3-
kinase activity in the absence of imatinib was normalized to 100%.
The respective bar graphs shown are the mean±SEM values from 3
to 4 experiments. The asterisk indicates a p<0.05 compared with the
respective PDGF-induced PI 3-kinase activity.
increases in intracellular PIP3 lipid species, which are critical
for neuronal cell survival [30].
PI 3-kinase activation and PIP3 production are critical for
neuronal cell survival and development, neurite formation and
elongation, and axon specification [38-40]. This effect has
been demonstrated in several neuronal cell types, including
RGCs  [41],  hippocampal  neurons  [38,42,43],  cerebellar
granule neurons [43], and PC12 cells [44]. Overexpression or
microinjection  of  constitutively  active  PI  3-kinase/Akt
promotes  neurite  outgrowth  and  neuronal  cell  survival
[45-47], whereas wortmannin inhibition of PI 3-kinase/Akt
Figure  8.  Time-dependent  effects  of  imatinib  on  PDGF-induced
versus insulin-induced Akt/GSK-3β/p70S6kinase phosphorylation.
Serum-deprived  (24  h)  RGC-5  cells  were  pretreated  without
(control) or with 10 µM imatinib for increasing time intervals (3 h
and 24 h). Subsequently, control and imatinib-treated cells were
stimulated with either 30 ng/ml PDGF or 30 nM insulin for 6 min.
The cell lysates were subjected to immunoblot analysis for Akt,
GSK-3β, and p70S6kinase phosphorylation (A-C, and D-F) using
the indicated primary antibodies (see Methods). To normalize the
changes in protein phosphorylation in the immunoblots, we used β-
actin as an internal control. Note: For data analyses, PDGF- or
insulin-induced protein kinase phosphorylation in the absence of
imatinib was normalized to 100%. The respective bar graphs shown
are the mean±SEM values from 3 to 4 experiments. The asterisk
indicates a p<0.05 compared with the respective PDGF-induced
protein kinase phosphorylation.
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[4,44]. The present observations from imatinib-treated RGCs
raise the possibility that an imbalance in IRS-dependent and
IRS-independent  PI  3-kinase  signaling  pathways  may
dysregulate neuronal cell phenotype by inhibiting neurite and
axon formation and inducing apoptosis.
Several studies have shown that IRS-dependent and IRS-
independent PI 3-kinase/Akt signaling pathways mediate the
survival of neuronal cells. In this regard, insulin and insulin-
like growth factor-1 utilize IRS as the intermediary signaling
component  to  activate  PI  3-kinase/Akt  survival  signaling
[11,40].  In  contrast,  growth  factors  (e.g.,  PDGF  and
hepatocyte  growth  factor)  and  neurotrophins  (e.g.,  brain-
derived  neurotrophic  factor,  neurotrophin-3,  and  nerve
growth  factor)  utilize  IRS-independent  mechanisms  to
Figure 9. Schematic showing imatinib dysregulation of PI 3-kinase/
Akt signaling in RGCs. PI 3-kinase is a heterodimer consisting of
p85 regulatory and p110 catalytic subunits. Imatinib inhibition of
PDGFR tyrosine kinase abrogates PDGF-induced PDGFR tyrosine
phosphorylation, p85 regulatory subunit recruitment, PI 3-kinase
activity, and the phosphorylation of downstream effectors such as
Akt,  GSK-3β,  and  p70S6kinase.  In  contrast,  imatinib  exposure
maintains  insulin  receptor-mediated  IRS-associated  PI  3-kinase
activity and the downstream phosphorylation of Akt, GSK-3β, and
p70S6kinase.  Thus,  an  imbalance  between  receptor-  and  IRS-
associated PI 3-kinase activity attenuates coordinated increases in
phosphatidylinositol 3,4,5-trisphosphate (PIP3) lipids. The resultant
diminutions in the overall phosphorylation of Akt, GSK-3β, and
p70S6kinase increase the propensity toward apoptotic cell death.
activate  PI  3-kinase/Akt  survival  signaling  [12,14,48-50].
Thus, several neurotrophic factors promote the survival of
neuronal cells by distinct activation of IRS-dependent or IRS-
independent PI 3-kinase, which results in the formation of
PIP3  species  and  downstream  phosphorylation  of  protein
kinases such as Akt, GSK-3β, and p70S6kinase. The present
study has employed a neuronal cell model system that directly
compares IRS-dependent and IRS-independent PI 3-kinase/
Akt  survival  signaling  after  stimulation  with  insulin  and
PDGF, respectively. Our observations provide the first direct
evidence  that  imatinib  disruption  of  PDGF-induced  IRS-
independent PI 3-kinase/Akt signaling is associated with the
induction of apoptosis, which is not prevented by apparent
increases in insulin-induced IRS-dependent PI 3-kinase/Akt
signaling  events.  The  inability  of  insulin  to  exhibit
neuroprotective  effects  under  these  conditions  strongly
suggests  that  PI  3-kinase/Akt  signaling  events  via  IRS-
dependent  and  IRS-independent  mechanisms  are  not
redundant but independent pathways for optimal survival of
neuronal cells.
At  this  juncture,  it  is  pertinent  to  note  that  imatinib
therapy  in  CML  patients  with  diabetes  improves  insulin
sensitivity and fasting blood glucose levels [24,25]. On the
contrary, recent studies with hepatoma cells have shown that
imatinib attenuates insulin-induced phosphorylation of Akt
and  glycogen  synthase  kinase-3β  (GSK-3β)  [26].  In  the
present study, imatinib treatment in RGCs maintains insulin-
induced PI 3-kinase/Akt signaling, which, however, is not
sufficient to prevent apoptotic cell death in the context of
abrogated PDGF receptor signaling. Future studies are clearly
warranted, and should determine the extent to which systemic
and ocular infusion of imatinib in rodent models affects PDGF
vs insulin-induced pro-survival signaling in the neuroretina.
PDGF exerts neuroprotective effects in several neuronal
cell  types.  After  optic  nerve  axotomy,  RGCs  undergo
apoptosis due to diminished PDGF expression levels [16]. In
hippocampal  neurons,  PDGF  protects  against  metabolic
insults resulting from energy deprivation and oxidative insults
arising from hydroxyl radical exposure [51]. In these neurons,
PDGF also inhibits N-methyl-D-aspartate (NMDA) receptor-
mediated excitotoxicity [52]. Notably, mouse brains deficient
in  neuronal  PDGF  receptor-β  are  vulnerable  to  cerebral
damage,  as  revealed  by  increased  neuronal  cell  death  by
NMDA  [18].  In  glioma  cells,  PDGF-induced  PI  3-kinase
signaling  enhances  cell  surface  expression  of  glutamate
transporters to promote glutamate transport activity, thereby
attenuating cytotoxicity arising from extracellular glutamate
[14]. In brainstem neurons, PDGF-induced PI 3-kinase/Akt
signaling  prevents  hypoxia-induced  apoptosis  [15,53].  In
neuroblastoma  cells,  PDGF  prevents  gp120-induced
cytochrome  C  release  and  apoptosis  [50].  Thus,  PDGF
promotes  neuronal  cell  survival  by  preventing  aberrant
processes that contribute to excitotoxic or apoptotic cell death.
Our  present  findings  with  RGC-5  cells  demonstrate  that
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with induction of apoptosis, which is not prevented by insulin.
Together, these data suggest that PDGF- and insulin-induced
PI 3-kinase/Akt signaling may differentially regulate diverse
cellular processes that are critical for neuronal survival.
RGC-5  cells  express  several  ganglion  cell  markers
including Thy-1 and NMDA receptors, and thereby possess
the characteristics of primary RGCs in culture [31,54]. In
addition,  RGC-5  cells  exhibit  glial-like  undifferentiated
phenotype [55]. Recent studies demonstrate that treatment of
RGC-5 cells with staurosporine, a broad-spectrum protein
kinase  inhibitor,  promotes  transition  of  undifferentiated
RGC-5 cells to a differentiated phenotype without inducing
apoptosis  [55].  Of  importance,  PDGF  receptor-deficient
neuroprogenitor cells exhibit increased apoptosis and reduced
capacity to differentiate in response to PDGF, suggesting the
importance of intact PDGF receptor signaling for neuronal
cell survival and differentiation [56]. Our present observations
with imatinib-treated RGC-5 cells suggest that the activation
of  PDGF  receptor  tyrosine  kinase  is  critical  for  retinal
neuronal cell survival.
PDGF  receptor  antagonism  induces  apoptotic  loss  of
RGCs  (present  study),  neuroprogenitor  cells  [56],  and
brainstem neurons [15]. In addition, imatinib inhibition of
PDGF receptor signaling is implicated in the development of
retinal edema [19-23] and cerebral edema [57]. The current
observations  of  imatinib-induced  apoptosis  in  retinal  cell
culture model may provide a possible explanation for these
observations but further studies are warranted. In conclusion,
the  present  findings  strongly  suggest  that  intact  PDGF
receptor  signaling  characterized  by  IRS-independent
activation of PI 3-kinase/Akt is critically important for retinal
neuronal cell survival.
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